600518 ST康美药业
2023/12 -
人民幣(K¥)

变动
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
2018/12
人民幣(K¥)
营业总收入4,874,01616.60%4,152,5215,412,00811,445,54617,065,079
减:营业总成本4,894,6180.10%6,519,6659,590,36714,821,12216,251,950
    其中:营业成本4,042,15913.96%3,486,2845,226,5269,935,09411,619,347
               财务费用27,118-33.59%1,064,4832,192,2912,262,3541,887,439
               资产减值损失(197,552)-60.26%(3,193,364)(25,279,869)(1,126,038)(238,989)
公允价值变动收益(35)----------
投资收益44,4345,849.29%188,785(4,591)767,70548,518
    其中:对联营企业和合营企业的投资收益--------83,40148,518
营业利润86,666-104.88%10,110,877(30,490,864)(3,869,060)686,921
利润总额110,367-104.14%8,155,293(31,033,477)(4,391,080)672,482
减:所得税费用6,800-77.14%235,38962,546264,128302,441
净利润103,567-103.84%7,919,904(31,096,023)(4,655,207)370,041
减:非控股权益1,046-118.54%2,003(11,191)5,468(4,451)
股东净利润102,521-103.81%7,917,901(31,084,832)(4,660,675)374,492

市场价值指针
每股收益 (元) *0.010-105.26%0.570-2.250-0.9900.030
每股派息 (元) *----------0.024
每股净资产 (元) *0.5081.44%0.716-2.0413.5285.072
审计意见 #标准无保留意见带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见--保留意见保留意见
回页顶
备注: *未调整数据
#只提供简体内容